

Consolidated Financial Results for Fiscal 2016

(Reference Data of Financial Statements for the 2Q of Fiscal 2016)

November 7, 2016

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: koho@kaken.co.jp

ACRUX DDS PTY LTD. et al.

EXHIBIT 1650

1. Summary of Consolidated Financial Statements for the Second Quarter of Fiscal 2016

(Figures less than one million yen have been omitted)

	FY2015 2nd Q	FY2015	FY2016 2nd Q	Y o Y increase (decrease)		FY2016 Forecasts	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	54,973	109,730	52,179	(2,793)	94.9%	106,100	(3,630)	96.7%
Operating income	18,443	35,146	16,123	(2,319)	87.4%	28,900	(6,246)	82.2%
Ratio of net sales	33.6%	32.0%	30.9%			27.2%		
Ordinary income	18,573	35,365	16,238	(2,335)	87.4%	29,100	(6,265)	82.3%
Ratio of net sales	33.8%	32.2%	31.1%			27.4%		
Net income	12,483	21,143	11,446	(1,037)	91.7%	20,800	(343)	98.4%
Ratio of net sales	22.7%	19.3%	21.9%			19.6%		
Per share profit (Yen)	301.39	510.54	278.02			508.90		

Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.
Per share profit has been calculated as if this consolidation of shares was conducted at the beginning of previous fiscal year.

Comprehensive income	11,308	18,444	11,597	288	102.6%			
Capital investment	1,529	2,923	861	(668)	56.3%	2,100	(823)	71.8%
R&D expenses	2,965	5,883	3,627	661	122.3%	10,200	4,317	173.4%
Depreciation and amortization	1,039	2,242	903	(135)	86.9%	2,100	(142)	93.7%
Employee number	1,482	1,451	1,443	(39)				

2. Breakdown of Consolidated Net Sales by Segment

(Figures less than one million yen have been omitted)

	FY2015 2nd Q	FY2015	FY2016 2nd Q	Y o Y increase (decrease)	
				Yen	%
Pharmaceuticals, medical devices & agrochemicals	53,794	107,391	50,988	(2,805)	94.8%
Real estate	1,178	2,338	1,190	12	101.0%
Total	54,973	109,730	52,179	(2,793)	94.9%

KAKEN PHARMACEUTICAL CO., LTD.

3. Summary of Consolidated Balance Sheets

(Figures less than one million yen have been omitted)

	As of September 30, 2015	Ratio	As of March 31, 2016	Ratio	As of September 30, 2016	Ratio	Y o Y increase (decrease)
Assets	124,299	100.0%	132,991	100.0%	131,648	100.0%	(1,343)
Current assets	79,022	63.6%	88,991	66.9%	87,134	66.2%	(1,856)
Noncurrent assets	45,277	36.4%	43,999	33.1%	44,513	33.8%	513
Liabilities	38,714	31.1%	43,116	32.4%	36,911	28.0%	(6,205)
Current liabilities	31,727	25.5%	33,861	25.5%	28,224	21.4%	(5,636)
Noncurrent liabilities	6,986	5.6%	9,255	7.0%	8,686	6.6%	(568)
Net assets	85,585	68.9%	89,875	67.6%	94,736	72.0%	4,861
Capital stock	23,853	19.2%	23,853	17.9%	23,853	18.1%	—
Capital surplus	11,407	9.2%	11,407	8.6%	11,407	8.7%	—
Retained earnings	62,765	50.5%	68,609	51.6%	76,826	58.4%	8,217
Treasury stock	(16,271)	(13.1%)	(16,301)	(12.3%)	(19,807)	(15.0%)	(3,506)
Valuation difference on available-for-sale securities	4,188	3.4%	4,423	3.3%	4,355	3.3%	(68)
Remeasurements of defined benefit plans	(357)	(0.3%)	(2,117)	(1.6%)	(1,897)	(1.4%)	219

4. Summary of Consolidated Statements of Cash Flows

(Figures less than one million yen have been omitted)

	FY2015 2nd Q	FY2015	FY2016 2nd Q	Y o Y increase (decrease)
Net cash provided by (used in) operating activities	10,551	27,067	5,699	(4,851)
Net cash provided by (used in) investing activities	(1,754)	(4,105)	(2,151)	(397)
Net cash provided by (used in) financing activities	(2,821)	(5,984)	(6,729)	(3,908)
Cash and cash equivalents at end of period	30,742	41,744	38,562	7,819

KAKEN PHARMACEUTICAL CO., LTD.

5. Summary of Non-consolidated Financial Statements for the Second Quarter of Fiscal 2016

(Figures less than one million yen have been omitted)

	FY2015 2nd Q	FY2015	FY2016 2nd Q	Y o Y increase(decrease)		FY2016 Forecasts	Y o Y increase(decrease)	
				Yen	%		Yen	%
Net sales	53,851	107,627	51,406	(2,445)	95.5%	104,400	(3,227)	97.0%
Operating income	18,119	34,468	16,069	(2,050)	88.7%	28,800	(5,668)	83.6%
Ratio of net sales	33.6%	32.0%	31.3%			27.6%		
Ordinary income	18,277	34,743	16,183	(2,094)	88.5%	29,000	(5,743)	83.5%
Ratio of net sales	33.9%	32.3%	31.5%			27.8%		
Net income	12,295	18,757	11,411	(883)	92.8%	20,700	1,943	110.4%
Ratio of net sales	22.8%	17.4%	22.2%			19.8%		
Capital investment	1,508	2,897	861	(647)	57.1%	2,100	(797)	72.5%
R&D expenses	2,965	5,883	3,627	661	122.3%	10,200	4,317	173.4%
Depreciation and amortization	998	2,160	903	(95)	90.5%	2,100	(60)	97.2%
Export volume	5,088	10,137	3,438	(1,649)	67.6%			
Pharmaceuticals	4,231	7,859	2,616	(1,615)	61.8%			
Agrochemicals	856	2,277	822	(34)	96.0%			
Employee number	1,475	1,444	1,436	(39)				

6. Breakdown of Non-consolidated Net Sales by Segment

(Figures less than one million yen have been omitted)

	FY2015 2nd Q	FY2015	FY2016 2nd Q	Y o Y increase(decrease)		FY2016 Forecasts	Y o Y increase(decrease)	
				Yen	%		Yen	%
Pharmaceuticals & medical devices	50,790	100,062	47,831	(2,958)	94.2%	96,180	(3,882)	96.1%
Agrochemicals	2,080	5,620	2,384	304	114.6%	5,870	250	104.4%
Renting real estate	981	1,944	1,190	209	121.3%	2,350	406	120.9%
Total	53,851	107,627	51,406	(2,445)	95.5%	104,400	(3,227)	97.0%

Note: The Company absorbed and merged with KAKEN REALTY & SERVICE CO., LTD. as of March 31, 2016. Non-consolidated financial results for the six-month period of fiscal 2016 include a portion of sales previously recorded at KAKEN REALTY & SERVICE CO., LTD., such as net sales to external customers.

KAKEN PHARMACEUTICAL CO., LTD.

7. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

(Figures less than one million yen have been omitted)

	FY2015 2nd Q	FY2015	FY2016 2nd Q	%	FY2016 Forecasts	%
Anti-osteoarthritis Artz	15,659	30,760	14,955	95.5%	29,300	95.3%
Anti-nail fungus Clenafin	9,804	19,868	11,639	118.7%	23,800	119.8%
Post-operative anti-adhesive Seprafilm	5,641	11,262	5,536	98.1%	11,400	101.2%
Anti-hyperlipidemia Lipidil	2,237	4,526	2,227	99.5%	4,400	97.2%
Wound healing agent Fiblast Spray	1,816	3,617	1,846	101.6%	3,700	102.3%
Generic products	6,584	13,292	5,984	90.9%	12,700	95.5%
Sales of Jublia*	3,474	5,722	1,331	38.3%	4,100	71.7%

(*including sales of API and finished product, royalty revenue, milestone revenue and initial payment)

8. Development Status

Code	Indication	Stage	Remarks
KAG-308	Ulcerative colitis	PII	Developed jointly with Asahi Glass Co., Ltd.; Oral-use prostaglandin analog
BBI-4000	Primary focal hyperhidrosis	Preparing for PII	Licensed from Brickell Biotech, Inc.; Topical anticholinergic
KMW-1	Removal of eschar with thermal burns	Preparing for clinical trial	Licensed from MediWound Ltd.; Topically-applied enzymatic product Overseas product name : NexoBrid

KAKEN PHARMACEUTICAL CO., LTD.